← Shelf·GHRH analog + GHRP·VII.
CJC-1295 / Ipamorelin (No DAC).
A blend of two peptides: CJC-1295 (a modified 30-residue GHRH analog with amino acid substitutions for enhanced stability) and Ipamorelin (a pentapeptide growth-hormone secretagogue receptor agonist). Sold in the 'No DAC' configuration — the drug affinity complex modification is omitted, shortening plasma half-life.
Both components engage receptors your pituitary already uses to time growth-hormone release: the GHRH receptor (CJC-1295's target) and the GHSR/ghrelin receptor (Ipamorelin's target). This blend is engineered to signal both axes together.
Sold in stacks with confidence that the primary literature doesn't quite share. Both peptides are real, characterized compounds; the CJC/Ipamorelin combination protocol is largely researcher-and-clinic tradition, not a controlled published study.
Straight talk
Straight talk: the individual peptides have published receptor pharmacology and animal-model work. The specific CJC-1295 + Ipamorelin combination, at the doses and frequencies commonly discussed online, has essentially no published human trial evidence. This is research chemistry, not validated therapy.
What the research studies
The literature, not a summary of it.
The upstream GHRH work is Guillemin/Vale-lineage. Ipamorelin came out of Novo Nordisk secretagogue research (Raun, Hansen, and colleagues). Journals: Eur J Endocrinol, J Endocrinol, Growth Horm IGF Res. Read the research yourself:
Recommended vendor · Amino Club
≥ 99% by HPLC on the current lot — ILS Laboratories (ISO/IEC 17025). Vendor SKU is the blend, No DAC configuration.
$38.99 during Fall Sale (was $59.99)
35% off applied automatically at checkout when you land through this link.